🔗 Share this article

While the United States proceeds with sweeping changes to its vaccine guidelines, an unexpected name has emerged unexpectedly: Høeg, an American of Danish descent sports medicine doctor and epidemiologist who initially gained attention by questioning COVID-19 vaccinations throughout the global health crisis and has zeroed in on possible fatalities after COVID-19 immunization in her short position at the US Food and Drug Administration (FDA).

Proposed Overhauls to Pediatric Immunization Schedule

Agency leaders were set to unveil radical revisions to the pediatric vaccine schedule in December, bringing the US with Denmark’s vaccine program, it is understood – a major change that would put the US out of step with many the world with no evidence for public health gain. The announcement has been postponed until the new year.

Rather than the top vaccines chief, Høeg is set to speak at the gathering. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth individual to run the center this calendar year.

Consolidating Power at the Agency

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and vaccine centers as Høeg and Dr. Prasad solidify control at the regulatory agency – and it points to a increased emphasis upon rolling back long-standing vaccines at the FDA.

The new acting director has repeatedly called for ending some childhood immunization guidelines in the US so as to align more in line with the Danish model, a society with comprehensive healthcare and a number of inhabitants approximately the population of Wisconsin’s.

In her initial public appearances, she has continued to focus on immunizations – typically the domain of Prasad, chief of the FDA’s CBER – rather than drug regulation.

Concerns Over Expertise

The appointee has no apparent background in medication creation, oversight or administrative roles, which has been standard for previous leaders of the CBER. She has worked at the FDA as a top consultant to the agency head and the vaccine center since earlier this year.

“It seems she lacks to have the necessary background” for running the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She’s never run a scientific study. She lacks experience in managing a major agency. She is not an expert in pharmaceutical oversight.”

Previous commissioners of CBER would “be deeply familiar with regulatory frameworks and the research of pharmaceutical innovation”, noted a former acting FDA commissioner. “Frankly, she doesn’t have the kind of background that prior appointees who ran CBER have had.”

CDER has an immense workload at the FDA, Woodcock stated.

“Many people just pays attention on the new drug program, but the generic drug division approves numerous off-brand pharmaceuticals. There’s a biologic copycat branch, over-the-counter program and more, and all of those need to be supervised,” she explained. “The area you neglect, that is the part that I always told people is going to come back to haunt you.”

Additionally, a substantial leadership component to the job, which supervises more than 5,000 staff members. “It is a huge leadership role, if you do it right,” the former official concluded.

Response and Contentious Initiatives

When asked about inquiries about Høeg’s fitness for the role and whether this assignment indicates increased cooperation among agency officials on vaccines, a press secretary responded that the “inquiries rely on inaccurate assumptions”.

“This background matches the duties of her job,” the official stated, pointing to the time Dr. Høeg spent advising the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s controversial priority voucher program, a disputed expedited therapy clearance system that reportedly worried her predecessors. “How are these drugs being picked for this fast-track system? Who makes the decisions?” Howard asked. “There’s a lot of lack of transparency going on at the agency right now.”

In general, he said, “the agency seems to be moving towards less stringent rules of pharmaceuticals, with the exception of shots.”

Documented History on Immunizations

With immunizations, Høeg has a more established, if problematic, track record, critics have noted. She published a research paper using non-validated crowd-sourced reports to determine the frequency of heart inflammation after Covid vaccination. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to suggest Covid vaccines are pose a greater threat than they are.

Part of her “desired changes” for the current administration encompassed revising regulations for recently developed shots and halting “optional” immunizations, she remarked post-election on a online show. At the FDA, Dr. Høeg has reportedly proposed excluding adolescent males from obtaining Covid vaccinations.

“She is an complete dogmatist who starts off with her beliefs and reverse-engineers to fit the evidence in a very deceptive, fraudulent way,” Dr. Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg aligned with other contrarians, {like|